Radiation Oncologist @Unispital_USZ | former research scholar @MSKCancerCenter | interested in 🫁, reirradiation & oligometastatic disease
Zurich, Switzerland
Joined March 2014
- Tweets485
- Following720
- Followers474
- Likes1.5K
Pinned Tweet
Current classifications of OMD assign one state per patient. But within the same patient, lesions respond, persist, and progress on divergent paths.
We propose metastatic trajectories – a lesion-level framework to guide local + systemic therapy in metastatic NSCLC.
📄 @JCO_ASCO
ALT 📄 @JCO_ASCO https://ascopubs.org/doi/full/10.1200/JCO-25-01958
Jonas Willmann, MD retweeted
#ESMO26 Dr. @fifimcdrmh presents the SARON trial. Phase II of consolidation radiotherapy vs systemic therapy in pts with driver negative oligometastatic NSCLC after 6-8w of control with systemic therapy. Improvement in PFS with radiation 13.9 vs 8.9m but no difference in OS.
Jonas Willmann, MD retweeted
Presenting the UK’s SARON study Dr @fifimcdrmh to a full hall at #ESMO26
In patients with de novo oligometastatic mutation driver negative #NSCLC , consolidation radiotherapy to the primary and metastases improved PFS but no OS
No significant difference in QOL or AEs
Huge thanks to all the patients and trialists involved
Jonas Willmann, MD retweeted
Now in Nature w simultaneous presentation #ESMO26 #NeoCOAST2 ! 1st platform neoadjuvant trial to associate tumor agnostic ctDNA dynamics w pCR & EFS! Privileged to be part of this effort led by Drs. Lara McGrath & Tina Cascone! Paper/slides below! 1/ #lcsm
nature.com/articles/s41586-0…
Jonas Willmann, MD retweeted
🚨🔥@OncoAlert Hot off the press.
Just published @NEJM in conjunction with presentation @myESMO #ESMO26
the long-awaited #PracticeChanging results of:
⭐️#DeLLphi305 phase 3 trial of:
❇️1st line maintenance #Tarlatamab + #Durvalumab) vs #Durvalumab alone in patients with #ExtensiveStage #SmallCell #LungCancer after initial induction Tx with #Chemo + Durvalumab.
Study showed:
‼️#Impressive statistically significant & clinically meaningful ⬆️#OverallSurvival Benefit.
✅#mOS: 21.1 vs 12.7 months (HR 0.42)
✅12-month OS: 79.4% vs 53.3%
✅#mPFS: 7.4 vs 1.9 months (HR 0.34)
⚠️ Grade ≥3 #AEs: 46.8% vs 40.6%
* In Tarlatamab arm:
#CRS: 49.6% (Grade ≥3: 0.4%)
#ICANS: 1.1% (Grade ≥3: 0%)
👇🏻
nejm.org/doi/full/10.1056/NE…
Jonas Willmann, MD retweeted
Yes, it works in pancreatic cancer.
🚨📣 big news at #ESMO26: 🧵1/MASTERPLAN RCT shows adding SABR to perioperative chemotherapy for high-risk localized #pancreatic cancer ⬆️⬆️ median overall survival to 22.0 months vs 14.0 months (HR 0.45). #PancreaticCancer #RadOnc @TROGfightcancer in press @TheLancetOncol - thelancet.com/journals/lanon…
Jonas Willmann, MD retweeted
DeLLphi-305 - tarlatamab added to durvalumab after initial chemo-immunotherapy for small lung cancer essentially doubles survival. Hope for all cancers here, if the right target & treatment modality can be refined. Unquestionably a new standard for this disease. #ESMO2026
Jonas Willmann, MD retweeted
🚨📣 big news at #ESMO26: 🧵1/MASTERPLAN RCT shows adding SABR to perioperative chemotherapy for high-risk localized #pancreatic cancer ⬆️⬆️ median overall survival to 22.0 months vs 14.0 months (HR 0.45). #PancreaticCancer #RadOnc @TROGfightcancer in press @TheLancetOncol - thelancet.com/journals/lanon…
Jonas Willmann, MD retweeted
Led by Drs @SafaviaA and @IMRTLee in @JAMAOnc: Can we safely reduce elective radiation dose in HPV+ oropharyngeal cancer?
Our study provides 5-yr evidence supporting elective nodal de-escalation to just 30 Gy, while maintaining excellent disease control.
jamanetwork.com/journals/jam…
Now in @JAMAOnc:
We report 5y outcomes post 30 Gy elective RT (total 70 Gy CCRT) for 276 pts w/ HPV-related OPC #hncsm at @MSKCancerCenter #radonc
LRC 97.0%
OS 90.8%
PFS 85.9%
DMFS 91.2%
@imrtlee @xrtGenomics @seanmmcbride @CJTsaiMDPhD @EChrisDee
👉 shorturl.at/liqpP
Jonas Willmann, MD retweeted
Congrats to the SARON investigators! Important randomized data for a question we face all the time. 👏
Consolidation RT improved local control and PFS, but no OS benefit demonstrated: HR 0.99 (95% CI 0.63-1.55).
The RT details caught my eye. Of 62 pts who received RT, 51 had conventional treatment to the primary and only 11 had primary SABR. About 53% of the full cohort had N2/3 disease.
Side note: in the separate 13-pt ESTRO safety substudy, the most common schedules were 55 Gy/20 fx to the primary (10/13 pts) and 27 Gy/3 fx to thoracic mets (4/14 lesions). Those are substudy doses, not the dose distribution for the whole trial.
Curious how pts who actually received SABR to all sites did. That would be exploratory, but I'd like to see the dose/volume details and patterns of failure before generalizing these results to patients receiving total consolidation.
Looking forward to the full paper! #ESMO26 #radonc
cslide.ctimeetingtech.com/es…
Jonas Willmann, MD retweeted
How to plan and deliver lung cancer reirradiation: A consensus approach from the ESTRO reirradiation and lung focus groups and ReCOG - Radiotherapy and Oncology thegreenjournal.com/article/…
Jonas Willmann, MD retweeted
🚨🔔🔔Very happy to announce that we have randomised the first patient into @TOGAANZ and @TROGfightcancer phase III, PRIME-lung trial! First site open @PeterMacCC
➡️ this newly open 420 patient phase III trial investigates whether the addition of high dose radiation to the lung primary in patients with non-small cell lung cancer can be life-prolonging (primary endpoint OS)
➡️ Thank you all investigators and patients, this is just the beginning! #lungcancer #lcsm
Jonas Willmann, MD retweeted
OptiTROP-Lung05: 🫁
A strong phase 3 signal for ADC + immunotherapy in 1L PD-L1+ advanced NSCLC.
Sac-TMT + pembrolizumab vs pembrolizumab:
• PFS: NR vs 5.7 months; HR 0.35
• ORR: 70.2% vs 42.0%
thelancet.com/journals/lance…
@OncoAlert #lcsm #LungCancer
Jonas Willmann, MD retweeted
📍 Yesterday at the European Parliament, Prof @piet_ost represented ESTRO for the launch of the EAU #KidneyCancer White Paper.
Multidisciplinary care saves lives when interventions like #SABR are accessible without disparity.
Thanks to our host MEPs and EAU! 🙏
#radonc #Urology
Jonas Willmann, MD retweeted
Proud of our @nyulangone Dean (and prior @Perlmutter_CC Director) Alec Kimmelman for his @Nature paper today:
Hepatocytes promote liver metastasis of #PancreaticCancer by providing serine
nature.com/articles/s41586-0…
With @BarDafna @RichPossemato @KoelinaG @nyugrossman
Jonas Willmann, MD retweeted
📜 In @JNCI_Now, we present "A phase II randomized study of proton therapy vs intensity-modulated radiation therapy in patients with unilateral head and neck cancer"
Thank you Drs @imrtlee @xrtGenomics & team @MSKCancerCenter @MiamiCancerInst @MayoRadOnc
pubmed.ncbi.nlm.nih.gov/4269…
🔵 Phase 2 (n = 98)randomized trial of proton beam RT vs IMRT in postoperative unilateral #HeadAndNeckCancer
➡️ Clinician-graded grade ≥2 mucositis 7.4% vs 22.7% (P=.03), dysgeusia 9.3% vs 31.8% (P=.005).
🔗: oxford.ly/4Ay4H9V
@IMRTLee | @xrtGenomics | @EChrisDee
Jonas Willmann, MD retweeted
🙏Thanks @crisbergerot for the mention.
#CURB2 @CDNCancerTrials needs everyone's support to answer this crucial question.
@NRGonc @ALLIANCE_org @SWOG @KHigginsMD @JAMRadOnc @DrAryaAmini @DrMengWelliver @DrewMoghanaki @NCICancerTrials @lungoncdoc @NarjustFlorezMD
CURB2 will determine whether targeting oligoprogression with SBRT can extend the benefit of first-line ICI-based therapy @JCOOA_ASCO @CJTsaiMDPhD @DrPOGaudreau
ascopubs.org/doi/pdf/10.1200…
Jonas Willmann, MD retweeted
We have waited more than a decade for this: ROAM is presented in Rome #EANO2026! See the results of ROAM/EORTC-1308, now also published in @TheLancet!
@EANOassociation
thelancet.com/journals/lance…
Jonas Willmann, MD retweeted
🏆IASLC Cancer Care Team Award Europe🏆
What a special moment at the @IASLC #WCLC2026 in Seoul!
I am incredibly proud that our multidisciplinary team has been honoured with the @IASLC Cancer Care Team Award for Europe.
This recognition reflects what truly defines modern cancer care: close collaboration across disciplines and professions, combining different perspectives and expertise with one common goal - providing the best possible care for our patients.
I am very grateful to share this recognition with an outstanding team: @HillingerSven , Annegret Hinkelmann, Albana Rexhepaj, @raph_werner, @jonas_willmann, Laura Boos, Gian-Marco Monsch, @OliviaLauk, @SilviaUlrich6, Carolin Steinack, Andreas Wicki, Caroline Hertler, @UszDidi, Ömer Senbaklavaci, @Mat_Guc
This award belongs to the entire team and represents the dedication, trust and interdisciplinary collaboration that make comprehensive cancer care possible every day.
I am deeply grateful for this recognition and very proud of what we have achieved together.
#WCLC2026 #IASLC #CancerCareTeamAwardEurope #LungCancer #ThoracicOncology
#MultidisciplinaryCare #Teamwork #ThoracicSurgery
Jonas Willmann, MD retweeted
Today, Memorial Sloan Kettering Cancer Center (MSK) and OpenEvidence announced a partnership to advance precision oncology. This partnership includes integration of OpenEvidence within MSK’s Epic workflow, and bringing OncoKB™, MSK's precision oncology knowledge base, directly into OpenEvidence for its broader use by physicians outside of @MSKCancerCenter.
“AI has the potential to fundamentally change how we translate an increasingly complex and rapidly expanding body of knowledge into better decisions for patients,” – Anaeze Offodile, M.D., Chief Strategy Officer at MSK.
Full press release:
mskcc.org/news-releases/mskc…
